Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBP-4888 in Preterm Preeclampsia
NCT07282171Phase 1Recruiting
- Sponsor
- Comanche Biopharma
- Start
- Feb 2025
- Primary completion
- Mar 2027
- Modality
- Conjugated siRNA, Small Molecules, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CBP-4888 in preeclampsia, sponsored by Comanche Biopharma. Primary endpoints: Incidence of treatment emergent events and adverse events of special interest and Recommended phase 2 dose. Started Feb 2025; status: recruiting.
02
Drugs
CBP-4888
03
Conditions
preeclampsia
Beyond the preview
Go deeper on NCT07282171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282171.